跳转至内容
Merck
CN
所有图片(1)

主要文件

查看所有文档

安全信息

C-053

Supelco

卡马西平标准液 溶液

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C15H12N2O
CAS号:
298-46-4
分子量:
236.27
MDL编号:
MFCD00005073
UNSPSC代码:
41116107
NACRES:
NA.24

等级

certified reference material

质量水平

300

表单

liquid

特点

SNAP-N-SPIKE®, SNAP-N-SHOOT®

包装

ampule of 1 mL

制造商/商品名称

Cerilliant®

浓度

1.0 mg/mL in methanol

技术

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

应用

clinical testing

包装形式

single component solution

储存温度

−20°C

SMILES字符串

O=C(N)N1C2=C(C=CC=C2)C=CC3=C1C=CC=C3

InChI

1S/C15H12N2O/c16-15(18)17-13-7-3-1-5-11(13)9-10-12-6-2-4-8-14(12)17/h1-10H,(H2,16,18)

InChI key

FFGPTBGBLSHEPO-UHFFFAOYSA-N

基因信息

human ... SCN10A(6336) , SCN11A(11280) , SCN1A(6323) , SCN2A(6326) , SCN3A(6328) , SCN4A(6329) , SCN5A(6331) , SCN7A(6332) , SCN8A(6334) , SCN9A(6335)

相关类别

一般描述

卡马西平是一种抗惊厥和稳定情绪的药物，主要用于治疗癫痫和神经性疼痛。 卡马西平以Carbatrol®，Tegretol®，Carbamaze和Biston商品名销售，也用作双相障碍的二线治疗，并与抗精神病药联合用于精神分裂症。这种经认证的加标溶液®的适当用途包括在临床毒理学、疼痛处方监测、法医分析或治疗药物监测应用的GC/MS或LC/MS卡马西平检测方法中，作为制备校准品和质控品的起始物料。

法律信息

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Carbatrol is a registered trademark of Pharmavene, Inc.
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Tegretol is a registered trademark of Novartis Corporation

警示用语：

Danger

危险分类

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - Skin Sens. 1 - STOT SE 1

靶器官

Eyes

储存分类代码

3 - Flammable liquids

WGK

WGK 1

闪点(°F)

49.5 °F - closed cup

闪点(°C)

9.7 °C - closed cup

法规信息

危险化学品

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助，请联系 客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Emilie Caietta et al.
Pediatrics, 132(3), e784-e787 (2013-08-21)
Mutations of SCN4A encoding the skeletal muscle sodium channel Nav 1.4 cause several types of disease, including sodium channel myotonias. The latter may be responsible for neonatal symptoms, including severe neonatal episodic laryngospasm (SNEL). Establishing the diagnosis of SCN4A-related SNEL
Inge Anita Meijer et al.
Muscle & nerve, 49(1), 134-138 (2013-07-31)
Erythromelalgia due to heterozygous gain-of-function SCN9A mutations usually presents as a pure sensory-autonomic disorder characterized by recurrent episodes of burning pain and redness of the extremities. We describe a patient with an unusual phenotypic presentation of gross motor delay, childhood-onset
U Amstutz et al.
Clinical pharmacology and therapeutics, 94(1), 142-149 (2013-04-17)
The occurrence of hypersensitivity reactions including rare but life-threatening Stevens-Johnson syndrome (SJS) and drug-induced hypersensitivity syndrome (HSS) limits the use of the anticonvulsant carbamazepine (CBZ). Human leukocyte antigen-B (HLA)-B 15:02 and HLA-A 31:01 have been identified as predictive genetic markers
Ursula Amstutz et al.
Epilepsia, 55(4), 496-506 (2014-03-07)
To systematically review evidence on genetic risk factors for carbamazepine (CBZ)-induced hypersensitivity reactions (HSRs) and provide practice recommendations addressing the key questions: (1) Should genetic testing for HLA-B*15:02 and HLA-A*31:01 be performed in patients with an indication for CBZ therapy
Anna Jurado et al.
Chemosphere, 115, 47-53 (2014-02-25)
This paper deals with urban groundwater contaminated with carbamazepine (CBZ) and five of its human metabolites in Barcelona. Groundwater samples were accordingly collected in the aquifers of Poble Sec and Besòs River Delta. Higher concentrations and more compounds were found
查看所有相关文献

商品

Protein Binding Determination Using Supel™ BioSPME C18 Pin Device as Part of the Manual Methodology With and Without Shaking

The application note describes a comparative analysis of plasma protein binding results for free/bound drugs using two different sample extraction steps, with and without agitation.

Speed, Simplicity and Accuracy of Protein Binding Determination using BioSPME

Learn about Supel™ BioSPME C18 high-throughput devices to determine plasma protein binding and decrease the sample preparation time to less than an hour.

Protein Binding Determination - Comparison Study of Techniques & Devices

Comparative analysis of Supel™ BioSPME 96-Pin device with a rapid equilibrium dialysis technique for accuracy of measured values, sample cleanliness, and workflow time in drug protein binding.

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持